JP2022532547A5 - - Google Patents

Info

Publication number
JP2022532547A5
JP2022532547A5 JP2021566106A JP2021566106A JP2022532547A5 JP 2022532547 A5 JP2022532547 A5 JP 2022532547A5 JP 2021566106 A JP2021566106 A JP 2021566106A JP 2021566106 A JP2021566106 A JP 2021566106A JP 2022532547 A5 JP2022532547 A5 JP 2022532547A5
Authority
JP
Japan
Prior art keywords
patient
composition according
oral immunotherapy
quality
period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021566106A
Other languages
English (en)
Japanese (ja)
Other versions
JP7574222B2 (ja
JP2022532547A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/032179 external-priority patent/WO2020231843A1/en
Publication of JP2022532547A publication Critical patent/JP2022532547A/ja
Publication of JP2022532547A5 publication Critical patent/JP2022532547A5/ja
Application granted granted Critical
Publication of JP7574222B2 publication Critical patent/JP7574222B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021566106A 2019-05-10 2020-05-08 ピーナツアレルギー患者の生活の質を改善するための方法 Active JP7574222B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962846481P 2019-05-10 2019-05-10
US62/846,481 2019-05-10
US201962855384P 2019-05-31 2019-05-31
US62/855,384 2019-05-31
US202062967948P 2020-01-30 2020-01-30
US62/967,948 2020-01-30
PCT/US2020/032179 WO2020231843A1 (en) 2019-05-10 2020-05-08 Methods for improving the quality of life of a patient with a peanut allergy

Publications (3)

Publication Number Publication Date
JP2022532547A JP2022532547A (ja) 2022-07-15
JP2022532547A5 true JP2022532547A5 (cg-RX-API-DMAC7.html) 2023-05-11
JP7574222B2 JP7574222B2 (ja) 2024-10-28

Family

ID=73289227

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021566106A Active JP7574222B2 (ja) 2019-05-10 2020-05-08 ピーナツアレルギー患者の生活の質を改善するための方法

Country Status (7)

Country Link
US (2) US11229673B2 (cg-RX-API-DMAC7.html)
EP (1) EP3965815A4 (cg-RX-API-DMAC7.html)
JP (1) JP7574222B2 (cg-RX-API-DMAC7.html)
CN (1) CN113966229A (cg-RX-API-DMAC7.html)
AU (1) AU2020276213A1 (cg-RX-API-DMAC7.html)
CA (1) CA3137295A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020231843A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
US12433945B2 (en) 2018-08-16 2025-10-07 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
CA3123605A1 (en) 2018-12-20 2020-06-25 Aimmune Therapeutics, Inc. Peanut oral immunotherapy dosing schedule for missed doses
JP7756664B2 (ja) 2020-07-01 2025-10-20 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 経口免疫療法のための医療スタッフ配置の決定
KR20230148769A (ko) 2022-04-15 2023-10-25 사회복지법인 삼성생명공익재단 경구면역요법을 이용한 식품알레르기 치료서비스 제공방법, 이를 구현하기 위한 기록매체에 저장된 컴퓨터 프로그램 및 시스템

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3809767A (en) 1969-05-12 1974-05-07 Griffith Laboratories Methods of making vegetable protein concentrates
AU1589492A (en) 1991-03-01 1992-10-06 Warner-Lambert Company Starch-based controlled release compositions
US20120164306A1 (en) 1993-08-03 2012-06-28 Girsh Leonard S Process for preparing hypoallergenic and reduced fat foods
JP3445593B2 (ja) 1994-09-10 2003-09-08 株式会社林原生物化学研究所 ペプチドとその用途
US20020018778A1 (en) 1999-12-06 2002-02-14 Caplan Michael J. Passive desensitization
EP1272213B1 (en) 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
WO2004047793A1 (en) 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
CA2516291C (en) 2003-02-28 2012-02-14 Alk-Abello A/S Dosage form having a saccharide matrix
EP2545931A1 (en) 2004-03-19 2013-01-16 Herbs Spring, LLC Herbal therapy for the treatment of food allergy
ATE524561T1 (de) 2004-04-06 2011-09-15 Sinai School Medicine Verfahren zur bestimmung einer allergenreaktion unter verwendung von mikroarray-immunoassay- techniken
WO2007075171A1 (en) 2005-12-28 2007-07-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of fenofibrate having improved bioavailability
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
BRPI0920465A2 (pt) 2008-10-02 2018-03-20 Salix Pharmaceuticals, Inc. metodo de tratamento de encefalopatia hepática
CN102215825A (zh) 2008-11-19 2011-10-12 安万托特性材料股份有限公司 可直接压制的颗粒状的基于微晶纤维素的赋形剂、其制备方法及应用
WO2010069595A1 (en) 2008-12-19 2010-06-24 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
EP2364690A1 (en) 2010-02-12 2011-09-14 Centro De Ingenieria Genetica Y Biotecnologia Orally administrable pharmaceutical pellet of epidermal growth factor
JP5800527B2 (ja) 2010-03-30 2015-10-28 日東電工株式会社 安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法
AR081776A1 (es) 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
GB201104537D0 (en) 2011-03-17 2011-05-04 Cambridge Entpr Ltd Treatment for peanut allergy
EP2750705B1 (en) 2011-08-31 2022-11-16 Perosphere Technologies Inc. Methods for effectively and rapidly desensitizing allergic patients
WO2013087119A1 (en) 2011-12-16 2013-06-20 Hal Allergy Holding B.V. Pharmaceutical formulations and the use thereof for the treatment of peanut allergy
PL2802333T3 (pl) 2012-01-13 2020-09-07 Chr. Hansen A/S Lactobacillus rhamnosus i Bifidobacterium animalis subsp. lactis do stosowania dla zapobiegania lub leczenia zakażeń górnych dróg oddechowych
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
MX2015010315A (es) 2013-03-14 2016-04-13 Aimmune Therapeutics Inc Fabricacion de formulaciones de mani para desensibilizacion oral.
CA2907915C (en) 2013-04-03 2023-03-07 Allertein Therapeutics, Llc Immunomodulatory nanoparticle compositions comprising a plurality of nanoparticles comprising biodegradable or biocompatible polymers and hydrophilic and hydrophobic cellular components
US9456628B2 (en) 2013-06-13 2016-10-04 D&E Gillespie Enterpries LLC Methods and products to provide oral nutritional care to subjects with dementia
US20150343075A1 (en) 2014-06-02 2015-12-03 Aimmune Therapeutics Placebo formulations and uses thereof
JP6910946B2 (ja) 2014-08-25 2021-07-28 アイミューン セラピューティクス,インコーポレイテッド タマゴのタンパク質製剤およびその製造方法
KR102234319B1 (ko) 2014-09-04 2021-04-01 헬신 헬쓰케어 에스.에이. 아나모렐린 기반의 의학적 치료
AU2015315628A1 (en) 2014-09-08 2017-04-20 Cephalon, Inc. Use of reslizumab to treat moderate to severe eosinophilic asthma
CN110381749A (zh) 2017-01-13 2019-10-25 艾慕恩治疗公司 坚果粉的制造方法和用于口服免疫疗法的配方
FR3062797B1 (fr) 2017-02-10 2025-03-07 Centre Hospitalier Et Univ De Clermont Ferrand Gelule a liberation gastro-intestinale destinee a etre utilisee dans une methode permettant de desensibiliser et/ou d'induire une tolerance chez un sujet allergique a l'arachide
US11369676B2 (en) * 2017-11-02 2022-06-28 Société des Produits Nestlé S.A. Methods of oral immunotherapy
USD866320S1 (en) 2018-07-27 2019-11-12 Aimmune Therapeutics, Inc. Box of boxes for dispensing medicine
USD866322S1 (en) 2018-07-27 2019-11-12 Aimmune Therapeutics, Inc. Medicine folio
US11406563B2 (en) 2018-07-27 2022-08-09 Société des Produits Nestlé S.A. Oral immunotherapy unit dose dispensing systems and methods
USD866321S1 (en) 2018-07-27 2019-11-12 Aimmune Therapeutics, Inc. Box of boxes for dispensing medicine
US12433945B2 (en) * 2018-08-16 2025-10-07 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
AU2019401576A1 (en) 2018-12-17 2021-06-24 Société des Produits Nestlé S.A. Formulations for egg oral immunotherapy, methods of manufacture, and treatments for egg allergy
CA3123605A1 (en) 2018-12-20 2020-06-25 Aimmune Therapeutics, Inc. Peanut oral immunotherapy dosing schedule for missed doses
JP7536035B2 (ja) 2019-03-22 2024-08-19 ソシエテ・デ・プロデュイ・ネスレ・エス・アー ピーナツに対する経口免疫療法における全身性アレルギー応答リスク評価
WO2020237181A1 (en) 2019-05-23 2020-11-26 Aimmune Therapeutics, Inc. Methods of treating peanut allergy by oral immunotherapy with low-dose maintenance

Similar Documents

Publication Publication Date Title
Donovan et al. Contemporary diagnosis and management of dental erosion
Lamster et al. The aging mouth: differentiating normal aging from disease
Amato et al. Assessment of sleep bruxism, orthodontic treatment need, orofacial dysfunctions and salivary biomarkers in asthmatic children
Attin et al. Composite vertical bite reconstructions in eroded dentitions after 5· 5 years: a case series
US11033543B2 (en) Methods of providing weight loss therapy in patients with major depression
CN1293573A (zh) 迟发性运动障碍和其它运动疾病的治疗方法
AlShahrani et al. Restorative rehabilitation of a patient with dental erosion
Oh et al. Open Proximal Contact with Implant-Supported Fixed Prostheses Compared with Tooth-Supported Fixed Prostheses: A Systematic Review and Meta-analysis.
JPS6345218A (ja) D―フェンフルラミン含有うつ病用医薬組成物
Terézhalmy et al. Physical evaluation in dental practice
Assaf et al. Four-year follow-up of increased vertical dimension of occlusion using resin composites
CN116033900A (zh) 治疗冠状病毒暴露所致疾病的方法
Goldstein et al. Oral habits
Rafatjou et al. A multidisciplinary approach to a seven year-old patient with incontinentia pigmenti: a case report and five-year follow up
Diniz et al. Dental erosion in pediatric dentistry: What is the clinical relevance
PK et al. Association of recurrent aphthous ulcers with stress among students in an Indian dental institution
Wilson et al. Cohen syndrome: case report
Gerasimidou et al. Changes in Tooth Mobility and Position in an Established Dentition Following Placement of a New Restoration
Aronson Sleep Disordered Breathing Risk in Surgical and Early Class II Correction Orthodontic Population
Meehan Screening for dental disease amongst elite athletes
Fan et al. MCQs for dentistry
AU2023367071A1 (en) Ulotaront for treating anxiety and associated conditions
Sever 5th International Congress of the School of Dental Medicine University of Zagreb: March 1-2, 2019, School of Dental Medicine and Hotel Westin Zagreb/5 Medunarodni kongres Stomatoloskog fakulteta Sveucilista u Zagrebu: 1. i 2. ozujka 2019., Stomatoloski fakultet, Gunduliceva 5, Zagreb i Hotel Westin Zagreb.
Chaudhary et al. Russell-Silver syndrome: A case report with review of literature
US20140323577A1 (en) Methods for reducing the risk of conversion to clinically definite multiple sclerosis